These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

924 related items for PubMed ID: 30039219

  • 1. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
    Wei J, Yang G, Hao X, Gu D, Tan Y, Wang X, Dong D, Zhang S, Wang L, Zhang H, Tian J.
    Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
    [Abstract] [Full Text] [Related]

  • 2. Radiomics signature: A potential biomarker for the prediction of MGMT promoter methylation in glioblastoma.
    Xi YB, Guo F, Xu ZL, Li C, Wei W, Tian P, Liu TT, Liu L, Chen G, Ye J, Cheng G, Cui LB, Zhang HJ, Qin W, Yin H.
    J Magn Reson Imaging; 2018 May; 47(5):1380-1387. PubMed ID: 28926163
    [Abstract] [Full Text] [Related]

  • 3. Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas.
    Jiang C, Kong Z, Liu S, Feng S, Zhang Y, Zhu R, Chen W, Wang Y, Lyu Y, You H, Zhao D, Wang R, Wang Y, Ma W, Feng F.
    Eur J Radiol; 2019 Dec; 121():108714. PubMed ID: 31704598
    [Abstract] [Full Text] [Related]

  • 4. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study.
    Li ZC, Bai H, Sun Q, Li Q, Liu L, Zou Y, Chen Y, Liang C, Zheng H.
    Eur Radiol; 2018 Sep; 28(9):3640-3650. PubMed ID: 29564594
    [Abstract] [Full Text] [Related]

  • 5. A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery.
    Tan Y, Zhang ST, Wei JW, Dong D, Wang XC, Yang GQ, Tian J, Zhang H.
    Eur Radiol; 2019 Jul; 29(7):3325-3337. PubMed ID: 30972543
    [Abstract] [Full Text] [Related]

  • 6. 18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma.
    Kong Z, Lin Y, Jiang C, Li L, Liu Z, Wang Y, Dai C, Liu D, Qin X, Wang Y, Liu Z, Cheng X, Tian J, Ma W.
    Cancer Imaging; 2019 Aug 19; 19(1):58. PubMed ID: 31426864
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
    Huang WY, Wen LH, Wu G, Hu MZ, Zhang CC, Chen F, Zhao JN.
    J Comput Assist Tomogr; 2019 Aug 19; 45(1):110-120. PubMed ID: 33475317
    [Abstract] [Full Text] [Related]

  • 10. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
    Wick A, Kessler T, Platten M, Meisner C, Bamberg M, Herrlinger U, Felsberg J, Weyerbrock A, Papsdorf K, Steinbach JP, Sabel M, Vesper J, Debus J, Meixensberger J, Ketter R, Hertler C, Mayer-Steinacker R, Weisang S, Bölting H, Reuss D, Reifenberger G, Sahm F, von Deimling A, Weller M, Wick W.
    Neuro Oncol; 2020 Aug 17; 22(8):1162-1172. PubMed ID: 32064499
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
    Han Y, Yan LF, Wang XB, Sun YZ, Zhang X, Liu ZC, Nan HY, Hu YC, Yang Y, Zhang J, Yu Y, Sun Q, Tian Q, Hu B, Xiao G, Wang W, Cui GB.
    BMC Cancer; 2018 Feb 21; 18(1):215. PubMed ID: 29467012
    [Abstract] [Full Text] [Related]

  • 13. Quality assessment of the MRI-radiomics studies for MGMT promoter methylation prediction in glioma: a systematic review and meta-analysis.
    Doniselli FM, Pascuzzo R, Mazzi F, Padelli F, Moscatelli M, Akinci D'Antonoli T, Cuocolo R, Aquino D, Cuccarini V, Sconfienza LM.
    Eur Radiol; 2024 Sep 21; 34(9):5802-5815. PubMed ID: 38308012
    [Abstract] [Full Text] [Related]

  • 14. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W, Ren X, Cai J, Zhang C, Li M, Wang K, Liu Y, Han S, Wu A.
    Oncotarget; 2015 Oct 06; 6(30):29285-95. PubMed ID: 26320189
    [Abstract] [Full Text] [Related]

  • 15. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA, He YL, Etcheverry A, Liu YH, Aubry M, Barnholtz-Sloan J, Liu BL, Mosser J, Lu ZF, Zhang X.
    Clin Epigenetics; 2019 May 14; 11(1):76. PubMed ID: 31088577
    [Abstract] [Full Text] [Related]

  • 16. Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
    Gramatzki D, Felsberg J, Hentschel B, Wolter M, Schackert G, Westphal M, Regli L, Thon N, Tatagiba M, Wick W, Schlegel U, Krex D, Matschke J, Roth P, Suresh MP, Kamp MA, Rushing EJ, Pietsch T, von Deimling A, Sabel M, Loeffler M, Weller M, Reifenberger G.
    Eur J Cancer; 2021 Apr 14; 147():84-94. PubMed ID: 33631540
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.
    Ochsenbein AF, Schubert AD, Vassella E, Mariani L.
    J Neurooncol; 2011 Jun 14; 103(2):343-51. PubMed ID: 20857319
    [Abstract] [Full Text] [Related]

  • 19. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
    Yuan G, Niu L, Zhang Y, Wang X, Ma K, Yin H, Dai J, Zhou W, Pan Y.
    J Neurooncol; 2017 May 14; 133(1):193-201. PubMed ID: 28516344
    [Abstract] [Full Text] [Related]

  • 20. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
    van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, Ibdaih A, Brandes AA, Taphoorn MJ, Frenay M, Lacombe D, Gorlia T, Dinjens WN, Kros JM.
    J Clin Oncol; 2009 Dec 10; 27(35):5881-6. PubMed ID: 19901104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.